Paradigm Therapeutics, Inc. Announces an Additional Investment by Eshelman Ventures, LLC to Expedite Global Development and Global Registration of SD-101, A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)

First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing...

Read more
Page 91 of 1123 1 90 91 92 1,123

Welcome Back!

Login to your account below

Retrieve your password

Please enter your username or email address to reset your password.